Kaunas, [25th February 2026] Biomapas, a leading integrated Life Sciences services provider, is announcing the appointment of Xavier Duburcq as Chief Executive Officer. He succeeds David Passov, who is stepping down following a mutually agreed leadership transition after successfully guiding the company through an important phase of development.
Xavier Duburcq brings extensive international leadership experience in life sciences and healthcare services. Throughout his career, he has built and led high-performing teams by rallying people around ambitious entrepreneurial projects, fostering innovation, and delivering sustainable long-term value creation.
His appointment marks the beginning of a new chapter for Biomapas as the company prepares to accelerate its next phase of growth.
During his tenure, David Passov led Biomapas through a pivotal period, including the acquisition of Delta PV, which significantly strengthened the company’s pharmacovigilance capabilities. Under his leadership, Biomapas reinforced its operational platform and laid a strong foundation for continued development.
Carbyne Equity Partners, majority shareholder of Biomapas, expressed its appreciation for David’s leadership and contribution during this important chapter.
David Passov commented:
“It has been a privilege to lead Biomapas during such a meaningful phase of its journey. I leave with deep pride in our shared accomplishments and great confidence in Biomapas’ continued success.”
Carbyne Equity Partners added:
“We sincerely thank David for his commitment and impact during a key transition period. We are delighted to welcome Xavier Duburcq as CEO. His leadership style, international experience, and ability to build strong, aligned organizations make him ideally suited to lead Biomapas forward.”
Xavier Duburcq said:
“I am truly excited to join Biomapas at this important moment in its development. I would like to sincerely thank David for his leadership and for the strong foundation he has built. I look forward to working closely with our teams and clients to strengthen impact, foster innovation, scale our capabilities, and unlock the full potential of Biomapas across markets.”
With a strong base in place, Biomapas now enters a new phase of accelerated development. Under Xavier Duburcq’s leadership and with the continued support of Carbyne Equity Partners, the company intends to scale into a €200 million-plus diversified pharma services platform. Growth will be driven by a combination of organic expansion and targeted M&A, strengthening scientific depth, expanding geographic footprint, and enhancing integrated capabilities across the value chain. Serving customers from emerging biotechnology companies to large global pharmaceutical groups, Biomapas is positioning itself as a long-term, integrated partner capable of supporting complex development needs with agility and expertise. By investing in talent, advancing innovation and digital capabilities, and reinforcing performance standards, the company is well positioned to accelerate sustainable growth and deliver meaningful long-term value to its clients worldwide.
About Biomapas
Biomapas is a leading pan-European integrated pharmaceutical services provider delivering tailored solutions across clinical trials, pharmacovigilance, medical information, regulatory affairs, and medical writing. Headquartered in Lithuania, Biomapas supports biotechnology, pharmaceutical, and medical device clients across the globe, combining global standards, local expertise, and technology-driven efficiencies. Learn more at www.biomapas.com.
About Carbyne Equity Partners
Carbyne Equity Partners is a private equity firm investing in growing European businesses with strong market positions and a commitment to innovation. Its focus spans healthcare, nutrition and agricultural inputs, sectors where the firm leverages its extensive network of entrepreneurial investors. Working closely with management teams, Carbyne supports businesses in accelerating growth and strengthening long-term market leadership. For more information, please visit www.carbynepartners.de.
About the Author
